Algert Global LLC Acquires 252,994 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Algert Global LLC lifted its position in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 214.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 370,958 shares of the company's stock after acquiring an additional 252,994 shares during the period. Algert Global LLC owned about 0.31% of 10x Genomics worth $8,376,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Allspring Global Investments Holdings LLC lifted its position in shares of 10x Genomics by 134.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,637 shares of the company's stock worth $32,000 after purchasing an additional 939 shares in the last quarter. GAMMA Investing LLC lifted its position in 10x Genomics by 451.8% in the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company's stock worth $35,000 after buying an additional 1,265 shares in the last quarter. Capital Performance Advisors LLP acquired a new stake in shares of 10x Genomics during the 3rd quarter valued at $35,000. First Horizon Advisors Inc. grew its holdings in shares of 10x Genomics by 74.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 1,898 shares of the company's stock valued at $37,000 after acquiring an additional 808 shares in the last quarter. Finally, Covestor Ltd increased its stake in shares of 10x Genomics by 501.7% in the first quarter. Covestor Ltd now owns 1,047 shares of the company's stock worth $39,000 after acquiring an additional 873 shares during the last quarter. Institutional investors and hedge funds own 84.68% of the company's stock.

10x Genomics Price Performance

10x Genomics stock traded up $1.02 during mid-day trading on Friday, reaching $14.31. The company had a trading volume of 5,631,208 shares, compared to its average volume of 2,044,426. The company has a 50 day moving average of $17.57 and a 200-day moving average of $19.93. 10x Genomics, Inc. has a 52 week low of $12.95 and a 52 week high of $57.90.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its earnings results on Tuesday, October 29th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.04. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. The business had revenue of $151.65 million during the quarter, compared to analysts' expectations of $158.84 million. During the same quarter last year, the company earned ($0.51) earnings per share. The firm's revenue was down 1.3% on a year-over-year basis. Analysts expect that 10x Genomics, Inc. will post -1.4 EPS for the current year.

Wall Street Analysts Forecast Growth

TXG has been the subject of a number of research reports. The Goldman Sachs Group reduced their price objective on 10x Genomics from $16.00 to $14.00 and set a "sell" rating for the company in a research report on Wednesday, October 30th. Barclays lowered their price target on 10x Genomics from $21.00 to $19.00 and set an "overweight" rating for the company in a research note on Friday, November 1st. Stephens reaffirmed an "overweight" rating and set a $30.00 price objective on shares of 10x Genomics in a research report on Thursday, October 10th. Leerink Partnrs raised shares of 10x Genomics to a "strong-buy" rating in a research report on Tuesday, September 3rd. Finally, Morgan Stanley cut their price target on shares of 10x Genomics from $50.00 to $46.00 and set an "overweight" rating on the stock in a report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, 10x Genomics currently has an average rating of "Moderate Buy" and an average price target of $29.19.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.